CI

At a glance

ClinicalIndex Comparison Record
Phase 2Recruiting· 106 target
Drug / intervention
Induction therapydrug
Likely dose
Not stated in record
Key inclusion· 12
  • ✓Metastatic, recurrent, or unresectable advanced TNBC
  • ✓PD-L1 positivity confirmed by SP142 IC ≥1
  • ✓At least 6 months from completion of curative treatment to first recurrence
  • ✓ECOG performance status 0-1
Key exclusion· 24
  • ✕Active brain metastases or carcinomatous meningitis
  • ✕History of invasive malignancy within 3 years (exceptions: basal cell, squamous cell carcinoma of skin, or carcinoma in situ)
  • ✕Concurrent or metachronous bilateral invasive breast cancer (unless both TNBC and PD-L1 positive)
  • ✕Radiotherapy within 14 days prior to enrollment

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06793553
NCT06793553Phase 2RecruitingMonitorUpdated 17mo ago · Completion was 3mo ago
Slow Enrollment
Monitor
CompareCT.gov

Randomized Phase II Trial Evaluating the Efficacy of Paclitaxel+Bevacizumab INDUCtion Followed by at atEzolizumab+Nab-paclitaxel for PD-L1-positive Metastatic Triple Negative Breast Cancer (JBCRG-M10, CMA-0196) (INDUCE Trial)

Japan Breast Cancer Research Group·interventional·Posted Jan 27, 2025·Updated Jan 30, 2025

In Brief

A Phase 2 clinical trial evaluating Induction therapy for Metastatic Breast Cancer. Currently recruiting, targeting 106 participants across 1 site.

Signals

Enrolling slower than its timeline implies

Detailed Summary

The objective of this research is to evaluate the efficacy of the treatment strategy to administer atezolizumab + nab-paclitaxel (PTX) following 2 cycles of induction therapy with PTX + bevacizumab (induction treatment strategy) in programmed cell death ligand-1 (PD-L1)-positive metastatic triple-negative breast cancer (mTNBC) in comparison with the standard atezolizumab + nab-PTX therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Breast Cancer
CountriesJapan
CollaboratorsChugai Pharmaceutical

Timeline

Phase 2Recruiting
2025202620272028
First PostedJan 27, 2025
Enrollment StartSep 13, 2024
Primary CompletionMar 31, 2026
Study CompletionSep 30, 2028
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 1.4 years ago

Interventions

Induction therapydrug

2 cycles of PTX+ bevacizumab induction therapy followed by atezolizumab+nab-PTX